CANA 300 mg (N = 114) | 94.4 ± 25.9 | −3.8 | −3.7* | |||||||
*p < 0.001 vs. PBO | ||||||||||
HbA1C (%) at 52 Weeks | ||||||||||
Baseline Mean ± SD | LS Mean Change (95% CI) | LS Mean Change (95% CI) | ||||||||
PBO/SITA (N = 115) | 8.0 ± 1.0 | - | - | |||||||
CANA 100 mg (N = 113) | 8.0 ± 0.9 | −0.92 (−1.06, −0.79) | - | |||||||
CANA 300 mg (N = 114) | 7.9 ± 0.9 | −1.03 (−1.17, −0.89) | - | |||||||
FPG (mg/dL) at 52 Weeks | ||||||||||
Baseline Mean | LS Mean Change (95% CI) | Difference vs. PBO | ||||||||
PBO/SITA (N = 115) | 164.0 ± 39.6 | - | - | |||||||
CANA 100 mg (N = 113) | 169.4 ± 39.6 | −26.7 (−32.4, −21.1) | - | |||||||
CANA 300 mg (N = 114) | 164.0 ± 41.4 | −31.5 (−37.2, −25.8) | - | |||||||
Body Weight (kg) at 52 Weeks | ||||||||||
Baseline Mean | LS Mean Percent Change (95% CI) | Difference vs. PBO | ||||||||
PBO/SITA (N = 115) | 93.8 ± 22.4 | - | - | |||||||
CANA 100 mg (N = 113) | 94.2 ± 22.2 | −2.7 (−3.6, −1.9) | - | |||||||
CANA 300 mg (N = 114) | 94.4 ± 25.9 | −3.7 (−4.6, −2.9) | - | |||||||